1 Outcome evaluation of health promotion/life style change Wei-Chu Chie.

Slides:



Advertisements
Similar presentations
Appraisal of an RCT using a critical appraisal checklist
Advertisements

The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011.
THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*
天 津 医 科 大 学天 津 医 科 大 学 Clinical trail. 天 津 医 科 大 学天 津 医 科 大 学 1.Historical Background 1537: Treatment of battle wounds: 1741: Treatment of Scurvy 1948:
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Design and Analysis of Clinical Study 12. Randomized Clinical Trials Dr. Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.
Clinical Trials Medical Interventions
Critical Appraisal for MRCGP Jim McMorran Coventry GP GP trainer Editor GPnotebook (
The Diabetes Prevention Program 10 Year follow-up Long-term Follow-up to A Randomized Clinical Trial to Prevent Type 2 Diabetes in Persons at High Risk.
Clinical Trials Hanyan Yang
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Experimental Study.
Studying treatment of suicidal ideation & attempts: Designs, Statistical Analysis, and Methodological Considerations Jill M. Harkavy-Friedman, Ph.D.
Prevention of Diabetes in African American Communities: Project PROUD Community Trevor Hart, Betty Kennedy, Susan Peterson, Guido Urizar, Ben Van Voorhees,
The effects of initial and subsequent adiposity status on diabetes mellitus Speaker: Qingtao Meng. MD West China hospital, Chendu, China.
Medical Management of obesity Perinatal ANGELS Conference Feb 17, 2005 Philip A. Kern.
© 2003 By Default! A Free sample background from Slide 1 Information Technology- Based Mechanism for the Management of Obesity.
CHP400: Community Health Program - lI Mohamed M. B. Alnoor Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past:
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.
Lecture 16 (Oct 28, 2004)1 Lecture 16: Introduction to the randomized trial Introduction to intervention studies The research question: Efficacy vs effectiveness.
Journal Club Sidharth Bagga MD. Cytisus laborium L. (Golden rain acacia)
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Quality of life improves after patients switch to biphasic insulin aspart 30/70 (BIAsp 30): IMPROVE™ Study data from 39,015 patients M. Benroumpi 1, T.
Lecture 17 (Oct 28,2004)1 Lecture 17: Prevention of bias in RCTs Statistical/analytic issues in RCTs –Measures of effect –Precision/hypothesis testing.
Reducing the Risk of T2DM: What Works?
An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
Outcome research 1 Introduction edu.tw.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Diabetes Prevention for a Heterogeneous Population Richard Arakaki, M.D. Professor of Medicine and Chief, Division of Endocrinology and Metabolism John.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
CHP400: Community Health Program - lI Research Methodology STUDY DESIGNS Observational / Analytical Studies Present: Disease Past: Exposure Cross - section.
Agresti/Franklin Statistics, 1 of 56  Section 4.3 What Are Good Ways and Poor Ways to Experiment?
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Lecture 5 Objective 14. Describe the elements of design of experimental studies: clinical trials and community intervention trials. Discuss the advantages.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Clinical trial The Way We Make Progress Against Disease Prof. Ashry Gad Mohamed Prof. of Epidemiology College of Medicine & KKUH.
Health Disparities/ Diabetes Care Sheldon Greenfield, MD Orange County Diabetes Education Collaborative Conference January 31, 2009.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
Clinical trial 2. Objective To evaluate efficacy and safety of varenicline for smoking cessation compared with sustained-release bupropion (bupropion.
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
A Diabetes Outcome Progression Trial
بسم الله الرحمن الرحيم جامعة أم درمان الإسلامية كلية الطب و العلوم الصحية - قسم طب المجتمع مساق البحث العلمي / الدفعة 21 Basics of Clinical Trials.
Confidential All Rights Reserved Patients Complain About Access Doctors Complain About Compliance.
Community based integrated intervention for prevention and management of Chronic Obstructive Pulmonary Disease in Guangdong, China: cluster randomised.
Alcohol Screening and Brief Interventions for Patients with Non-communicable Diseases Thomas F. Babor Department of Community Medicine University of Connecticut.
Prevention Of Diabetes. Type 2 Diabetes: Hyperglycemia Insulin Resistance Relative Impairment of Insulin Secretion Pathogenesis: Poorly Understood Genetic.
Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.
Diabetes Prevention Program (DPP)
1 Lecture 11: Cluster randomized and community trials Clusters, groups, communities Why allocate clusters vs individuals? Randomized vs nonrandomized designs.
Investigation 5-2 Did the prevention strategy work? xxxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxxxxxxx.
OFEV ® (nintedanib) TOMORROW trial results Last updated These slides are provided by Boehringer Ingelheim for medical to medical education only.
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
Silaja Cheruvu, R3.  What’s the BEST way to prevent diabetes in high risk patients?  By doing nothing?  With lifestyle changes?  With medication?
CDA exercise guidelines 150 minutes moderate – intensity (60 – 70% of max) aerobic over minimum 3 non consecutive days PLUS resistance exercise 3.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
1 Effect of Ramipril on the Incidence of Diabetes The DREAM Trial Investigators N Engl J Med 2006;355 FM R1 윤나리.
Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.
Angela Aziz Donnelly April 5, 2016
1 Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled.
Diabetes and Obesity Journal Club Carina Signori, D.O., M.P.H.
HOPE: Heart Outcomes Prevention Evaluation study
Randomized Trials: A Brief Overview
Design of Clinical Trials
Cluster Randomized Trials
ACC 2018 Orlando, Florida Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes A Pre-Specified Secondary Endpoint from.
ASPIRE CLASS 6: Interpreting Results and Writing an Abstract
1 Verstovsek S et al. Proc ASH 2012;Abstract Cervantes F et al.
Presentation transcript:

1 Outcome evaluation of health promotion/life style change Wei-Chu Chie

2 Health promotion Primary prevention –life style change –education and health behavior

3 Three elements for health promotion Experiment unit –Individual or group (cluster), usually healthy Treatments –education Evaluation –efficacy –safety: less serious and sometimes overlooked

4 Basic characteristics Difficult to follow the rule of randomized controlled double- blinded trials –placebo control with blindness: difficult to make and keep –individual randomization not convenient requires a large sample size –low incidence of the disease to prevent –low incidence of adverse effects

5 Major difficulties (1) No blindness: –Hawthorn effect and information bias –Rater blindness loyalty to the original randomization –Compliance or adherence –‘ Contamination ’ of the control group: got the intervention content elsewhere or from the treatment group

6 Major difficulties (2) Randomization unit –individual: ideal but difficult to implement –group (cluster): easy to implement but has statistical problem

7 ethical concerns administered on healthy people –autonomy emphasized: informed consent –safety less serious than immunization and drug, sometimes overlooked

8 Examples –Diabetes Prevention Program Research Group. Reduction in the incidence or type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346: –Brown KS, et al. Outcome evaluation of a high school smoking reduction intervention based on extracurricular activities. Prev Med 2002;35:

9 DM: background/goal/hypothesis Background: –burden of type 2 DM and delayed diagnosis –previous studies of its preventability Goal/hypothesis: –to determine whether... /DM is preventable by metformin and lifestyle intervention

10 DM: study design Randomized controlled trial –four groups … three two drugs (one DC due to serious AE) + lifestyle one placebo + lifestyle one intensive lifestyle –randomized by individual/stratified by centers –blinded only in the drug vs. placebo groups primary endpoint evaluated centrally/blind unaware of the test results in the middle

11 DM: subjects High-risk people at 27 centers four steps: – (the U.S.) , 3234 subjects (1082:1073:1079) –inclusion: 25 years+, BMI 24 or more, fasting glucose mg/dL, 2 hr 75-g GTT me/dL; half from minorities –exclusion: taking medicines, illness reducing life expectancy or ability to participate.

12 DM: exposure/intervention Group 1: standard lifestyle + metformin 850 mg qd to bid (GI symptoms) Group 2: … troglitazone … DC Group 3: intensive lifestyle Group 4: standard lifestyle + placebo (control)

13 DM: standard vs. intensive lifestyle Standard: –written form+individual session Intensive: –goal: weight reduction 7% –16-lesson curriculum, one-to-one for 1st 24 wks healthy low-calorie, low-fat diet physical activity of moderate intensity –subsequent sessions and group sessions

14 DM: endpoints Primary –efficacy: DM/ safety: adverse effects Secondary –weight, physical activity (MET), glucose Follow-up –annual o-GTT, semi-annual fasting plasma glucose/symptoms to planned 5/2001, actually on 3/31/2001 early stop due to advice from the monitoring board

15 DM: endpoints Definition of DM –abnormal o-GTT tests or fasting plasma sugar –confirmation by a second test within 6 weeks inform the patient and physician fasting sugar /6 months, HbA1c /year fasting sugar <140 mg /dL … continue fasting >= 140 mg/dL … DC and referral

16 DM: d ata analysis Basic characteristics and comparison –for confounding and possible selection bias Intention-to-treat analysis primary: time-to-event, survival (life- table) –modified product-limit … cumulative incidence –proportional hazards regression/ subgroup –persons need to treat secondary: fixed-effects models

17 DM: m ajor results/discussion –Comparison: Table 1 –Efficacy primary: Table 2, Figure 2 / subgroup analysis cumulative incidence P>M>L secondary: Figure 1, 3, 4 L has better weight reduction and increase in physical activity, similar or better glucose & HbA1c to M –Safety: Table 3 M has more GI & L has more MS symptoms

18 DM: m ajor results/discussion Discussion –Confounding, selection bias: randomization –Information bias: blindness –Early termination/ ethics –differentiation of diet and physical activity –Sample size and power of test Conclusion: L>=M>P

19 Smoking:background/goal/hypoth esis Background: –youth smoking rate and intervention –in-class vs. extra-curricular activities Goal/hypothesis: –to determine whether... extra- curricular activities can reduce teenage smoking rate

20 Smoking: study design Randomized controlled trial –two groups intervention usual care (control) –randomized by school (cluster) –no blindness

21 Smoking: subjects Waterloo, Canada Phase 1: 7 school boards/100 schools –teachers/ nurses social influence program –self-preparation materials –high-risk schools phase 2: 6 boards agreed/ 35 high- schools –30 schools agreed –matched within school board … pairs

22 Smoking: subjects Matching –by size, number and proportion of cohort students randomized into two groups –pairs: intervention vs. control grade 9 cohort attending the 30 schools –30 schools 15:15 –3028 students … :1465

23 Smoking: exposure/intervention Mobilizing staff and students/commitments A teacher facilitated students, staff, community participants in planning and implementing prevention and cessation activities … tailored to each school Role of research staff Budgets

24 Smoking: endpoints Primary –efficacy: smoking status –safety: no Secondary –No Follow-up –to grade 10

25 Smoking: endpoints Definition of smoking status By questionnaire: –never, –tried once, quit, experimental (< once/week) –regular (weekly) By CO breath samples

26 Smoking: d ata analysis Basic characteristics and comparison –for confounding and possible selection bias Intention-to-treat analysis Primary: –smoking status –subgroup analysis

27 Smoking: m ajor results/discussion Comparison: Table 1 Efficacy –Table 2 –subgroup analysis: –only effective for male non-smoker at grade 8 No other analyses

28 DM: m ajor results/discussion Discussion –Confounding, selection bias: randomization –Information bias: blindness –Sample size and power of test –Limited to one special group –Adverse effects not analyzed –Cost? Conclusion: limited!